Blog — brain health
Topical Progesterone, Not Synthetic Progestins or Oral Progesterone, Should Be Considered as a Companion for Estradiol Replacement Therapy
Posted by Ben White on
By Dr.David Zava, ZRT Laboratory In 2002 several large-scale clinical studies were published on the risks of breast cancer in postmenopausal women using conventional FDA-approved hormone therapy. These were the Women’s Health Initiative (WHI) and Million Women’s studies of women using FDA-approved estrogens and progestogens in the United States and Great Britain, respectively [1,2]. Both studies came to the same conclusion – that estrogen therapy, mostly in the form of oral conjugated equine estrogens, by itself did not significantly increase the risk of breast cancer and, to the surprise of many, was associated with a lower risk. However, when estrogen was...